256 related articles for article (PubMed ID: 31362695)
1. Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits.
Younis S; Faber BW; Kocken CHM; Remarque EJ
BMC Immunol; 2019 Jul; 20(1):25. PubMed ID: 31362695
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
[TBL] [Abstract][Full Text] [Related]
3. Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response.
Kusi KA; Faber BW; Riasat V; Thomas AW; Kocken CH; Remarque EJ
PLoS One; 2010 Nov; 5(11):e15391. PubMed ID: 21082025
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques.
Kusi KA; Remarque EJ; Riasat V; Walraven V; Thomas AW; Faber BW; Kocken CH
Malar J; 2011 Jul; 10():182. PubMed ID: 21726452
[TBL] [Abstract][Full Text] [Related]
5. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits.
Remarque EJ; Faber BW; Kocken CH; Thomas AW
Infect Immun; 2008 Jun; 76(6):2660-70. PubMed ID: 18378635
[TBL] [Abstract][Full Text] [Related]
6. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults.
Remarque EJ; Roestenberg M; Younis S; Walraven V; van der Werff N; Faber BW; Leroy O; Sauerwein R; Kocken CH; Thomas AW
PLoS One; 2012; 7(6):e38898. PubMed ID: 22768052
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02
Berry AA; Gottlieb ER; Kouriba B; Diarra I; Thera MA; Dutta S; Coulibaly D; Ouattara A; Niangaly A; Kone AK; Traore K; Tolo Y; Mishcherkin V; Soisson L; Diggs CL; Blackwelder WC; Laurens MB; Sztein MB; Doumbo OK; Plowe CV; Lyke KE
Malar J; 2019 Jan; 18(1):13. PubMed ID: 30658710
[TBL] [Abstract][Full Text] [Related]
8. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
Draper SJ; Biswas S; Spencer AJ; Remarque EJ; Capone S; Naddeo M; Dicks MD; Faber BW; de Cassan SC; Folgori A; Nicosia A; Gilbert SC; Hill AV
J Immunol; 2010 Dec; 185(12):7583-95. PubMed ID: 21098232
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
10. Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.
Miura K; Herrera R; Diouf A; Zhou H; Mu J; Hu Z; MacDonald NJ; Reiter K; Nguyen V; Shimp RL; Singh K; Narum DL; Long CA; Miller LH
Infect Immun; 2013 May; 81(5):1491-501. PubMed ID: 23429537
[TBL] [Abstract][Full Text] [Related]
11. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.
Kennedy MC; Wang J; Zhang Y; Miles AP; Chitsaz F; Saul A; Long CA; Miller LH; Stowers AW
Infect Immun; 2002 Dec; 70(12):6948-60. PubMed ID: 12438374
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
13. Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria.
Drew DR; Hodder AN; Wilson DW; Foley M; Mueller I; Siba PM; Dent AE; Cowman AF; Beeson JG
PLoS One; 2012; 7(12):e51023. PubMed ID: 23227229
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
[TBL] [Abstract][Full Text] [Related]
16. Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.
Zhu D; McClellan H; Dai W; Gebregeorgis E; Kidwell MA; Aebig J; Rausch KM; Martin LB; Ellis RD; Miller L; Wu Y
Vaccine; 2011 May; 29(20):3640-5. PubMed ID: 21440641
[TBL] [Abstract][Full Text] [Related]
17. Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine.
Laurens MB; Kouriba B; Bergmann-Leitner E; Angov E; Coulibaly D; Diarra I; Daou M; Niangaly A; Blackwelder WC; Wu Y; Cohen J; Ballou WR; Vekemans J; Lanar DE; Dutta S; Diggs C; Soisson L; Heppner DG; Doumbo OK; Plowe CV; Thera MA
PLoS One; 2017; 12(3):e0173294. PubMed ID: 28282396
[TBL] [Abstract][Full Text] [Related]
18. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model.
Dutta S; Sullivan JS; Grady KK; Haynes JD; Komisar J; Batchelor AH; Soisson L; Diggs CL; Heppner DG; Lanar DE; Collins WE; Barnwell JW
PLoS One; 2009 Dec; 4(12):e8138. PubMed ID: 19997632
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.
Pierce MA; Ellis RD; Martin LB; Malkin E; Tierney E; Miura K; Fay MP; Marjason J; Elliott SL; Mullen GED; Rausch K; Zhu D; Long CA; Miller LH
Vaccine; 2010 Mar; 28(10):2236-2242. PubMed ID: 20051276
[TBL] [Abstract][Full Text] [Related]
20. Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines.
Faber BW; Younis S; Remarque EJ; Rodriguez Garcia R; Riasat V; Walraven V; van der Werff N; van der Eijk M; Cavanagh DR; Holder AA; Thomas AW; Kocken CH
Infect Immun; 2013 May; 81(5):1479-90. PubMed ID: 23429538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]